RhumbLine Advisers’s enVVeno Medical NVNO Stock Holding History

RhumbLine Advisers’s Portfolio NVNO Stock Details NVNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-18	Closed	-$2.49K	–	4167
2025 Q2	$2.49K	Hold	18	–	–	﹤0.01%	3976
2025 Q1	$1.64K	Hold	18	–	–	﹤0.01%	3998
2024 Q4	$1.89K	Hold	18	–	–	﹤0.01%	4042
2024 Q3	$2.1K	Buy	+18	New	+$3.31K	﹤0.01%	4054

Other funds holding NVNO

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RhumbLine Advisers's NVNO Position: Q3 2025 in Review

RhumbLine Advisers sold out of enVVeno Medical (NVNO) in Q3 2025, closing a stake of 18 shares — an estimated $2.49K sold.

RhumbLine Advisers first reported a position in NVNO in Q3 2024 and held it in 4 quarters. The position peaked at $2.49K in Q2 2025. 36 funds tracked by Wall St. Rank hold NVNO as of Q3 2025.

RhumbLine Advisers reported no remaining enVVeno Medical position as of Q3 2025 after selling out during the quarter.
RhumbLine Advisers sold 18 enVVeno Medical shares in Q3 2025, an estimated $2.49K.
RhumbLine Advisers first reported a position in enVVeno Medical in Q3 2024 and held it in 4 quarters.
RhumbLine Advisers's enVVeno Medical position peaked at $2.49K in Q2 2025.
36 funds tracked by Wall St. Rank held enVVeno Medical as of Q3 2025.

Based on RhumbLine Advisers's 13F filing for Q3 2025, filed 6 Nov 2025.